Current and emerging investigational medical therapies for the treatment of overactive bladder.
Overactive bladder (OAB) is a chronic distressing condition characterised by urinary urgency with or without urge incontinence, usually with frequency (voiding at least eight times daily) and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is relatively higher in women compared with men. The treatment of OAB is aimed at reducing the debilitating symptoms so as to improve the overall quality of life for patients. Anticholinergic agents targeting the muscarinic receptors in the bladder represent the mainstay of pharmacotherapy for the treatment of OAB. Besides their status as the current standard of care, use of antimuscarinic drugs is limited by certain side effects, particularly dry mouth and constipation; therefore, various attempts have been made to improve the organ selectivity of these drugs to overcome the side effects. These include the development of new antimuscarinic agents with structural modifications and the use of innovative drug delivery methods. The advancement in the drug delivery systems extends to the long-term therapeutic efficacy with improved tolerability and patient compliance; however, future prospective therapies are aimed at novel targets with novel mechanisms of action, including beta3-adrenoceptor agonists, K+ channel openers, 5-HT modulators and botulinum toxin, which are currently under different stages of clinical development. Among other investigational therapies, neurokinin receptor antagonists, alpha-adrenoceptor antagonists, nerve growth factor inhibitors, gene therapy and stem cell-based therapies are of considerable interest. The future for the development of new modalities for the treatment of OAB looks promising.
Tiwari
Atul
A
Ranbaxy Research Laboratories, Urology and Metabolic Group, NDDR, Gurgaon-122001, Haryana, India. naruganahalli.krishna@ranbaxy.com
Naruganahalli
Krishna S
KS
D000818:Animals; D004337:Drug Carriers; D015195:Drug Design; D015316:Genetic Therapy; D006801:Humans; D018727:Muscarinic Antagonists / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*
D004337:Drug Carriers; D018727:Muscarinic Antagonists